Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
Anthony D'UrzoDepartment of Family and Community Medicine, University of Toronto, Toronto, ON, CanadaAbstract: Progressive airflow limitation is a hallmark feature of chronic obstructive pulmonary disease (COPD) that ultimately leads to breathlessness, impaired quality of life, and reduced e...
Main Author: | D’Urzo A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-08-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/role-of-once-daily-glycopyrronium-bromide-nva237-in-the-management-of--a14077 |
Similar Items
-
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
by: D'Urzo Anthony, et al.
Published: (2011-12-01) -
Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
by: Beeh KM, et al.
Published: (2012-07-01) -
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
by: Buhl R, et al.
Published: (2012-10-01) -
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
by: Buhl R, et al.
Published: (2014-03-01) -
Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
by: Mantero M, et al.
Published: (2018-07-01)